CT-155 is a smartphone app that integrates psychosocial interventions delivered using an adaptive goal-setting technique. A phase 3 trial has demonstrated that it can reduce the negative symptoms of schizophrenia.

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA

Few movies and TV shows accurately depict schizophrenia, and even fewer feature women with the condition—which undoubtedly plays a role in the misconception that schizophrenia only occurs in men. The truth is that rates of the condition are pretty evenly ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires cautious adoption and patient-centered decision-making in clinical practice.

German drugmaker Boehringer Ingelheim and Click Therapeutics said their phase 3 trial of a prescription digital therapeutic for the negative symptoms of schizophrenia met its primary endpoint.

Schizophrenia is a severe and debilitating psychiatric disorder characterized by hallucinations, disorganized speech and thought patterns, false beliefs about the world or oneself, difficulties concentrating and other symptoms impacting people's daily functioning.

Shares of Minerva Neurosciences surged more than fourfold after the company said it has secured up to $200 million in financing to advance an investigational schizophrenia treatment through a phase 3 trial.